Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Obstetricia y Ginecología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 2
ClinicalTrials.gov
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
INTERVENTIONAL
Inicio: 1 de oct de 2007
ID: NCT00455533
Completado
Fase 2
ClinicalTrials.gov
Phase II Trial of Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
INTERVENTIONAL
Inicio: 1 de nov de 2003
ID: NCT00072852
Completado
Fase 2
ClinicalTrials.gov
A Multicenter Open-Label Single-Arm Phase II Study Evaluating the Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Metastatic, Recurrent or Persistent Cervical Cancer
INTERVENTIONAL
Inicio: 28 de jul de 2015
ID: NCT02467907
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Patients With HER2-Positive Early Breast Cancer
INTERVENTIONAL
Inicio: 19 de dic de 2018
ID: NCT03674112
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Open-label Study to Compare the Effect of First-line Treatment With Avastin in Combination With Herceptin/Docetaxel and Herceptin/Docetaxel Alone on Progression-free Survival in Patients With HER2 Positive Locally Recurrent or Metastatic Breast Cancer.
INTERVENTIONAL
Inicio: 1 de sept de 2006
ID: NCT00391092
Terminado
Fase 3
ClinicalTrials.gov
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab
INTERVENTIONAL
Inicio: 1 de abr de 2008
ID: NCT00625898
Reclutando
Fase 3
ClinicalTrials.gov
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
INTERVENTIONAL
Inicio: 5 de oct de 2023
ID: NCT05952557
Terminado
Fase 3
ClinicalTrials.gov
EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer
INTERVENTIONAL
Inicio: 22 de jul de 2021
ID: NCT04729387
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
INTERVENTIONAL
Inicio: 9 de abr de 2025
ID: NCT06790693
Completado
ClinicalTrials.gov
Effect of a Home-based Versus Supervised Exercise Program in Patients With Migraine: a Randomized Clinical Trial
INTERVENTIONAL
Inicio: 13 de jun de 2022
ID: NCT05292599
Completado
Fase 2
ClinicalTrials.gov
Phase II Study of Novel Epothilone (BMS-247550) in Patients With MBC Who Are Refractory to an Anthracycline, a Taxane, and Capecitabine
INTERVENTIONAL
Inicio: 1 de feb de 2004
ID: NCT00080262
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Open-Label, Phase III Study of RPR109881 IV Every 3 Weeks Versus Capecitabine (Xeloda) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients With Metastatic Breast Cancer Progressing After Taxanes and Anthracycline Therapy
INTERVENTIONAL
Inicio: 1 de abr de 2004
ID: NCT00081796
Desconocido
ClinicalTrials.gov
Multicentric Study of Cervical Cancer Screening and Triage With Human Papillomavirus (HPV) Testing
OBSERVATIONAL
Inicio: 1 de may de 2013
ID: NCT01881659
Completado
Fase 2
ClinicalTrials.gov
A Phase 2 Study of Alimta and Epirubicin Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer
INTERVENTIONAL
ID: NCT00097383
Por invitación
Fase 3
ClinicalTrials.gov
Open-label, Safety Extension Study for Subjects With HR+, HER2-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer OVELIA Study
INTERVENTIONAL
Inicio: 28 de dic de 2022
ID: NCT05645536
Completado
Fase 3
ClinicalTrials.gov
A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
INTERVENTIONAL
Inicio: 8 de nov de 2011
ID: NCT01358877
Desconocido
ClinicalTrials.gov
Study of the Best Blastocyst Post Transfer by aCGH
OBSERVATIONAL
Inicio: 1 de sept de 2012
ID: NCT01664546
Reclutando
ClinicalTrials.gov
A Multicentre Study Assessing Ophthalmic Safety in Patients With Breast Cancer
OBSERVATIONAL
Inicio: 4 de mar de 2025
ID: NCT06767462
Suspendido
Fase 3
ClinicalTrials.gov
MULTIMODALITY TREATMENT STRATEGY FOR STAGE III BREAST CANCER
INTERVENTIONAL
Inicio: 1 de oct de 1995
ID: NCT00002696
Completado
ClinicalTrials.gov
Avastin in First Line Metastatic or Recurrent Breast Cancer. Retrospective Phase IV Study
OBSERVATIONAL
Inicio: 1 de ene de 2010
ID: NCT01215123
Anterior
1
...
14
15
16
...
434
Siguiente
Filtros